Results 221 to 230 of about 13,561,049 (255)

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

open access: yesBMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li   +9 more
wiley   +1 more source

Programmable three‐state nanoreactor for spatiotemporally controlled tumor therapy

open access: yesBMEMat, EarlyView.
The OMVs are shielded with a biocompatible Da–Ca shell, which prolongs its circulation period and promotes intratumoral accumulation. Importantly, the biocompatible Da–Ca shell can be controllably disintegrated in tumor microenvironment by using laser irradiation, generating in situ hyperthermia and releasing Ca2+.
Guihong Lu   +12 more
wiley   +1 more source

Quercetin‐zinc coordination polymer coated CaCO3 nanoparticles potentiate radiotherapy through reprogramming tumor immunosuppression

open access: yesBMEMat, EarlyView.
Synthesis of QZCaCO3‐PEG to synergistically enhance the immunogenicity of radiotherapy through concurrent Zn2+‐induced cancer cell pyroptosis and Que‐mediated hypoxia amelioration through sequentially suppressing TGF‐β secretion and ECM deposition. Abstract Radiotherapy has demonstrated broad applications in treating solid tumors, but the hostile tumor
Chunjie Wang   +9 more
wiley   +1 more source

Hyperbranched poly‐L‐lysine surface‐engineered bioprosthetic heart valves with anti‐calcification, anti‐infection, and durability

open access: yesBMEMat, EarlyView.
The challenges of bioprosthetic heart valves (BHV) with respect to calcification, infection, and poor durability are tackled by surface engineering of hyperbranched poly‐L‐lysine (HBPL), providing a translational solution to improve long‐term valve performance.
Pai Peng   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy